HNF1A is also the gene responsible for (maturity onset diabetes of the young type 3 (MODY3), a rare monogenic cause of diabetes….
Read More »Joslin’s Diabetes Deskbook, Updated 2nd Ed., Excerpt #52: Pharmacotherapy of Type 2 Diabetes, Part 11
Richard S. Beaser, MD This week’s excerpt covers the following topics: What drugs restore incretin function How to titrate GLP-1 agonists Learn the contraindications and precautions for the DPP-IV inhibitors The typical doses for the different DPP-IV’s….
Read More »Tamara Hannon, MD, Q5: What Are Your Thoughts on Using Sulfonylureas in Children?
Dr. Tamara Hannon talks about the possibility of using one of the most common adult anti-diabetic medications, sulfonylureas, in children. However, she points out that the drugs can only help adults achieve metabolic control in the short-term which concerns her because children and teens with type 2 diabetes definitely need …
Read More »ADA: Inhaled Insulin, Will It Pass Muster?
Even if the FDA approves Technosphere Insulin Inhalation Powder (TI) in the US, will it get recommended?…
Read More »ADA 2014 – GLP-1 Update
For this month’s special feature we have a selection of the GLP-1 abstracts and releases from the recent American Diabetes Association’s 74th Scientific Sessions in San Francisco. New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes New Phase 3a findings show IDegLira, the …
Read More »Joslin’s Diabetes Deskbook, Updated 2nd Ed., Excerpt #51: Pharmacotherapy of Type 2 Diabetes, Part 10
Richard S. Beaser, MD Medications that Increase Insulin Secretion: SULFONYLUREAS CLASS SUMMARY: Action: Insulin secretagogues. Initial effects are to increase insulin secretory capacity. With establishment of long-term glucose control, this increase may not persist and other extrapancreatic effects, either direct or indirect, may also occur. Required for efficacy: Some remaining …
Read More »Adding Insulin as the Second Treatment for Type 2’s May Increase Risk of Death
Among diabetes patients receiving metformin, the addition of insulin compared with a sulfonylurea was associated with an increased risk of nonfatal cardiovascular outcomes and all-cause death….
Read More »Joslin’s Diabetes Deskbook, Updated 2nd Ed., Excerpt #50: Pharmacotherapy of Type 2 Diabetes, Part 9
Richard S. Beaser, MD This week’s excerpt covers the following topics: What drugs block glucose absorption How to titrate this class of drugs Learn the contraindications and precautions for the glucose blocking drugs Discover which other drugs can cause serious side effects when used with drugs that block glucose absorption …
Read More »Joslin’s Diabetes Deskbook, Updated 2nd Ed., Excerpt #49: Pharmacotherapy of Type 2 Diabetes, Part 8
Richard S. Beaser, MD This week’s excerpt covers the following topics: Drug interactions with potential for clinical significance for metformin Contraindications and precautions for metformin Class contraindications and precautions for TZD’s Which TZD interactions are serious and how it is metabolized
Read More »Joslin’s Diabetes Deskbook, Updated 2nd Ed., Excerpt #47: Pharmacotherapy of Type 2 Diabetes, Part 6
Richard S. Beaser, MD This week’s excerpt cover the following topics: Why a patient should start with multiple medications How much treatment is needed When to use combination therapy
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.